Christine BREFEL-COURBON

MCU-PH

Travaille sur

Abstracts rédigés ou co-rédigés

> Impact of foot reflexology on pain in Parkinson’s disease and on the functional connectivity of Neural Network Correlates of Pain
Karel Joineau, Estelle Harroch, Christine Brefel-Courbon, Emeline Descamps
FENS Regional Meeting FRM 2023
Algarve Portugal
> Étude des dimensions de personnalité du TCI chez des patients parkinsoniens fluctuants
Mathilde Boussac ; Christophe Arbus ; Olivier Colin ; Chloé Laurencin ; Alexandre Eusebio ; Elodie Hainque; Jean Christophe Corvol ; Nathalie Versace ; Olivier Rascol; Vanessa Rousseau ; Estelle Harroch ; Fabienne Ory Magne ; Margherita Fabbri ; Caroline Moreau ; Anne Sophie Rolland ; Béchir Jarraya ; David Maltête; Sophie Drapier ; Ana Raquel Marques ; Nicolas Auzou ; Thomas Wirth ; Mylène Meyer ; Bruno Giordana ; Mélissa Tir ; Tiphaine Rouaud ; David Devos ; Christine Brefel Courbon for the PREDISTIM study group
JNLF 2022 (Journées de Neurologie de Langue Française) :12 au 15 avril 2022 à Strasbourg.
> Quality of life improvement is associated with some personality dimensions in fluctuating Parkinson’s Disease patients after continuous subcutaneous apomorphine infusion
M. Boussac , E. Harroch , V. Rousseau , C. Barthelemy , C. Arbus , C. Brefel Courbon
ADPD 2022 (International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders) – 14-20 mars 2022 , Barcelone, Espagne.
> La personnalité impacte l’amélioration de qualité de vie des patients parkinsoniens après stimulation cérébrale profonde.
Boussac M, Arbus C, Bongeot G, et al.
11ème Congrès de l’Association Francophone de Psychologie de la Santé, Virtual 2021
> Part of personality is predictive of quality-of-life outcome after deep brain stimulation in Parkinson’s Disease.
Boussac M, Danaila T, Eusebio A, et al.
7th Congress of the European Academy of Neurology, Virtual 2021
> Les dimensions de personnalité sont associées à la qualité de vie chez les patients parkinsoniens avec des fluctuations motrices
Boussac M, Arbus C, Dupouy J, et al.
JNLF (Journées de Neurologie de Langue Française) Virtual Congress 2020
> The Association of Personality Dimensions with Quality of Life in Parkinson’s disease patients with motor fluctuations.
Boussac M, Arbus C, Dupouy J, et al.
EAN (European Academy of Neurology) Congress Virtual 2020

Publications rédigées ou co-rédigées

> 48- Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
Brefel-Courbon C, Harroch E, Marques A, Devos D, Thalamas C, Rousseau V, Ory-Magne F, Fabbri M, Maltête D, Rouaud T, Drapier S, Tir M, Thobois S, Salhi H, Corvol JC, Castelnovo G, Lagha-Boukbiza O, Fluchère F, Frismand S, Ansquer S, Sommet A, Rascol O.
Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
> 47- Personality and quality-of-life improvement after apomorphine infusion in Parkinson’s disease.
Boussac M, Harroch E, Barthelemy C, Ory-Magne F, Leung C, Fabbri M, Arbus C, Brefel-Courbon C.
Brain Commun. 2024 May 24;6(3):fcae181. doi: 10.1093/braincomms/fcae181.
> 43- French guidelines for the diagnosis and management of Tourette syndrome.
Hartmann A, Ansquer S, Brefel-Courbon C, Burbaud P, Castrioto A, Czernecki V, Damier P, Deniau E, Drapier S, Jalenques I, Marechal O, Priou T, Spodenkiewicz M, Thobois S, Roubertie A, Witjas T, Anheim M.
Rev Neurol (Paris). 2024 May 16:S0035-3787(24)00524-1. doi: 10.1016/j.neurol.2024.04.005.
> 28- Amantadine use in the French prospective NS-Park cohort.
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O; French N. S.-Park network.
J Neural Transm (Vienna). 2024 Apr 5. doi: 10.1007/s00702-024-02772-4.
> 25- Trial of Lixisenatide in Early Parkinson’s Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group.
N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323.
> 74- The effectiveness and safety of non-pharmacological intervention for pain management in Parkinson’s disease: A systematic review.
Huissoud M, Boussac M, Joineau K, Harroch E, Brefel-Courbon C, Descamps E.
Rev Neurol (Paris). 2023 Oct 11:S0035-3787(23)01041-X. doi: 10.1016/j.neurol.2023.04.010.
> 61- Impact of therapeutic education on the evolution of social representations of medication in patients with Parkinson’s disease: A quantitative and qualitative study (ETPARK REMED).
Faurie I, Harroch E, Scotto d’Apollonia C, Corte S, Arcari C, Mohara C, Barthelemy C, Fabre MH, Boussac M, Damase-Michel C, Almudever B, Croity-Belz S, Brefel-Courbon C.
Rev Neurol (Paris). 2023 Aug 24:S0035-3787(23)01004-4. doi: 10.1016/j.neurol.2023.03.026.
> 82- Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis.
Calvat P, Leung C, Bost C, Fortenfant F, Simonetta-Moreau M, Pariente J, Rafiq M, Brefel-Courbon C, Rascol O, Fabbri M, Ory-Magne F.
Parkinsonism Relat Disord. 2022 Dec 7:105232. doi: 10.1016/j.parkreldis.2022.105232.
> 81- Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson’s Disease.
into S, Nebel A, Rau J, Espesser R, Maillochon P, Niebuhr O, Krack P, Witjas T, Ghio A, Cuartero MC, Timmermann L, Schnitzler A, Hesekamp H, Meier N, Müllner J, Hälbig TD, Möller B, Paschen S, Paschen L, Volkmann J, Barbe MT, Fink GR, Becker J, Reker P, Kühn AA, Schneider GH, Fraix V, Seigneuret E, Kistner A, Rascol O, Brefel-Courbon C, Ory-Magne F, Hartmann CJ, Wojtecki L, Fradet A, Maltête D, Damier P, Le Dily S, Sixel-Döring F, Benecke P, Weiss D, Wächter T, Pinsker MO, Régis J, Thobois S, Polo G, Houeto JL, Hartmann A, Knudsen K, Vidailhet M, Schüpbach M, Deuschl G; EARLYSTIM Study Group.
Mov Disord. 2022 Dec 3. doi: 10.1002/mds.29282.
> 69- Genetic stratification of motor and QoL outcomes in Parkinson’s disease in the EARLYSTIM study.
Weiss D, Landoulsi Z, May P, Sharma M, Schüpbach M, You H, Corvol JC, Paschen S, Helmers AK, Barbe M, Fink G, Kühn AA, Courbon CB, Wojtecki L, Damier P, Fraix V, Houeto JL, Regis J, Sixel-Döring F, Pinsker MO, Thobois S, Gharabaghi A, Stoker V, Timmermann L, Schnitzler A, Krack P, Vidailhet M, Deuschl G, Krüger R.
Parkinsonism Relat Disord. 2022 Oct;103:169-174. doi: 10.1016/j.parkreldis.2022.08.025.
> 49- Can Dopamine Responsiveness Be Predicted in Parkinson’s Disease Without an Acute Administration Test?
Betrouni N, Moreau C, Rolland AS, Carrière N, Viard R, Lopes R, Kuchcinski G, Eusebio A, Thobois S, Hainque E, Hubsch C, Rascol O, Brefel C, Drapier S, Giordana C, Durif F, Maltête D, Guehl D, Hopes L, Rouaud T, Jarraya B, Benatru I, Tranchant C, Tir M, Chupin M, Bardinet E, Defebvre L, Corvol JC, Devos D; PREDISTIM Study Group.
J Parkinsons Dis. 2022 Jul 18. doi: 10.3233/JPD-223334.
> 5- The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
Tödt I, Al-Fatly B, Granert O, Kühn AA, Krack P, Rau J, Timmermann L, Schnitzler A, Paschen S, Helmers AK, Hartmann A, Bardinet E, Schuepbach M, Barbe MT, Dembek TA, Fraix V, Kübler D, Brefel-Courbon C, Gharabaghi A, Wojtecki L, Pinsker MO, Thobois S, Damier P, Witjas T, Houeto JL, Schade-Brittinger C, Vidailhet M, Horn A, Deuschl G.
Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28952.
> 85- Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson’s Disease (PSYCHO-STIM II).
Boussac M, Arbus C, Klinger H, Eusebio A, Hainque E, Christophe Corvol J, Rascol O, Rousseau V, Harroch E, d’Apollonia CS, Croiset A, Ory-Magne F, De Barros A, Fabbri M, Moreau C, Rolland AS, Benatru I, Anheim M, Marques AR, Maltête D, Drapier S, Jarraya B, Hubsch C, Guehl D, Meyer M, Rouaud T, Giordana B, Tir M, Devos D, Brefel-Courbon C; PREDISTIM study group.
J Parkinsons Dis. 2021 Dec 7. doi: 10.3233/JPD-212883.
> 42- A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson’s disease. The ERCOPARK study.
Fabbri M, Leung C, Baille G, Béreau M, Brefel Courbon C, Castelnovo G, Carriere N, Damier P, Defebvre L, Doe de Maindreville A, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F.
Parkinsonism Relat Disord. 2021 Jul 13;89:128-133. doi: 10.1016/j.parkreldis.2021.07.013.
> 31- Body mass index variations in patients with Parkinson’s disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
Fernández-Rodríguez B, Dupouy J, Harroch E, Fabre-Delcros MH, Barthélémy C, Loubière P, Barange K, Brefel-Courbon C, Rascol O, Ory-Magne F.
Rev Neurol (Paris). 2021 Jun 18:S0035-3787(21)00562-2. doi: 10.1016/j.neurol.2020.11.017.
> 2- Personality dimensions of patients can change during the course of parkinson’s disease.
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C; PREDI-STIM study group.
Voir la publication
PLoS One. 2021 Jan 7;16(1):e0245142. doi: 10.1371/journal.pone.0245142.
> 32- Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM).
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C; PREDI-STIM study group.
Voir la publication
J Parkinsons Dis. 2020 May 16. doi: 10.3233/JPD-191903.
> 53- Chronic pain in Parkinson’s disease: Clinical and pathophysiological aspects.
Marques A, Brefel-Courbon C.
Voir la publication
ev Neurol (Paris). 2020 Oct 2:S0035-3787(20)30677-9. doi: 10.1016/j.neurol.2020.06.015.
> 39- Programming parameters of subthalamic deep brain stimulators in Parkinson’s disease from a controlled trial.
Knudsen K, Krack P, Tonder L, Houeto JL, Rau J, Schade-Brittinger C, Hartmann A, Hälbig T, Paschen S, Barbe MT, Kühn A, Fraix V, Brefel-Courbon C, Vesper J, Maltête D, Sixel-Döring F, Weiss D, Witjas T, Thobois S, Agid Y, Schnitzler A, Schuepbach WMM, Timmermann L, Damier P, Vidailhet M, Deuschl G; EARLYSTIM study group.
Voir la publication
Parkinsonism Relat Disord. 2019 Jun 18. pii: S1353-8020(19)30244-5. doi: 10.1016/j.parkreldis.2019.05.023.
> 29- Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study.
Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M.
Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27727.
> 22- How to diagnose parkinsonian central pain?
Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C.
Parkinsonism Relat Disord. 2019 May 1. pii: S1353-8020(19)30220-2. doi: 10.1016/j.parkreldis.2019.04.025.
> 63- Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.
Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG.
Voir la publication
Parkinsonism Relat Disord. 2019 Jun;63:199-203. doi: 10.1016/j.parkreldis.2019.02.006. Epub 2019 Feb 5.
> 20- Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson’s disease cohort?
Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group.
Parkinsonism Relat Disord. 2019 Apr 25. pii: S1353-8020(19)30207-X. doi: 10.1016/j.parkreldis.2019.04.012.
> 58- Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease With Early Motor Complications.
Barbe MT, Tonder L, Krack P, Debû B, Schüpbach M, Paschen S, Dembek TA, Kühn AA, Fraix V, Brefel-Courbon C, Wojtecki L, Maltête D, Damier P, Sixel-Döring F, Weiss D, Pinsker M, Witjas T, Thobois S, Schade-Brittinger C, Rau J, Houeto JL, Hartmann A, Timmermann L, Schnitzler A, Stoker V, Vidailhet M, Deuschl G; EARLYSTIM study group.
Voir la publication
Mov Disord. 2019 Nov 22. doi: 10.1002/mds.27892.
> 57- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.
Voir la publication
Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Erratum in: Neurology. 2019 Jun 11;92(24):1166.
> 69- Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study.
Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M.
Voir la publication
Mov Disord. 2019 Aug;34(8):1210-1219. DOI:10.1002/mds.27727
> 7- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig T, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.
Neurology. 2019 Feb 8. pii: 10.1212/WNL.0000000000007037. doi: 10.1212/WNL.0000000000007037.
> 6- Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson’s disease: a correlation study.
Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C.
J Neural Transm (Vienna). 2019 Jan 31. doi: 10.1007/s00702-019-01974-5.
> 55- LRP10 in α-synucleinopathies.
Tesson C, Brefel-Courbon C, Corvol JC, Lesage S, Brice A; French Parkinson’s Disease Genetics Study Group.
Lancet Neurol. 2018 Dec;17(12):1034. doi: 10.1016/S1474-4422(18)30400-9. Epub 2018 Nov 13.
> 62- Centers for the management of Parkinson’s disease.
Brefel-Courbon C, Rémy P.
Rev Prat. 2018 May;68(5):520-521. French.
> 48- Molecular Imaging of Opioid System in Idiopathic Parkinson’s Disease.
Thobois S, Brefel-Courbon C, Le Bars D, Sgambato-Faure V.
Int Rev Neurobiol. 2018;141:275-303. doi: 10.1016/bs.irn.2018.07.029.
> 28- Cognitive complaint in early Parkinson’s disease: A pilot study.
Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.
Acta Neurol Scand. 2018 Jan;137(1):59-66. doi: 10.1111/ane.12808. Epub 2017 Aug 22.
> 66- Abnormal pain perception in patients with Multiple System Atrophy.
Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C.
Parkinsonism Relat Disord. 2017 Dec 8. pii: S1353-8020(17)30827-1. doi: 10.1016/j.parkreldis.2017.12.001.
> 41- Cognitive complaint in early Parkinson’s disease: A pilot study.
Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.
Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12808.
> 45- Parkinson’s patients can rely on perspective cues to perceive 3D space.
Séverac Cauquil A, Ory-Magne F, Jardiné V, Galitzky M, Rosito M, Brefel-Courbon C, Celebrini S.
Brain Res. 2017 May 15;1663:161-165. doi: 10.1016/j.brainres.2017.03.017. Epub 2017 Mar 19.
> 18- Other care in Parkinson’s disease: Psychological, rehabilitation, therapeutic education and new technologies.
Dupouy J, Ory-Magne F, Brefel-Courbon C.
Presse Med. 2017 Mar;46(2 Pt 1):225-232. doi: 10.1016/j.lpm.2016.11.009. Epub 2016 Dec 28. Review. French.
> 14- A longitudinal follow-up study of the quantiﬁcation of dopamine transporters with 123I-Ioﬂupane (DaTscan)
H. Fayolle, P. Gantet, A.S. Salabert, J. Delrieu, C. Brefel-Courbon, F. Ory-Magne, T. Voisin, P. Payoux
Médecine Nucléaire 41 (2017) 36-41
> 56- Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial.
Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Bérard E, Bourrel R, Molinier L, Brefel-Courbon C.
PLoS One. 2016 Sep 29;11(9):e0162646. doi: 10.1371/journal.pone.0162646.
> 51- Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man.
Saint-Aubert L, Pariente J, Dumas H, Payoux P, Brandel JP, Puel M, Vital A, Guedj E, Lesage S, Peoc’h K, Brefel Courbon C, Ory Magne F.
BMC Neurol. 2016 Jul 30;16:122. doi: 10.1186/s12883-016-0643-y.
> Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease.
Pellaprat J, Ory-Magne F, Canivet C, Simonetta-Moreau M, Lotterie JA, Radji F, Arbus C, Gerdelat A, Chaynes P, Brefel-Courbon C.
Parkinsonism Relat Disord. 2014 Jun;20(6):662-4. doi: 10.1016/j.parkreldis.2014.03.011.
> [A therapeutic educational program in Parkinson’s disease: ETPARK].
Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C.
Rev Neurol (Paris). 2014 Feb;170(2):128-33. doi: 10.1016/j.neurol.2013.08.007. French.
> Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network..
Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050.